Billionaire investor Stanley Druckenmiller is putting more money into biotech, and one name getting attention is $RVMD. The company is developing targeted cancer treatments, giving investors exposure to a potentially massive healthcare opportunity. Druckenmiller’s position adds another layer of interest, but biotech can be a high-risk space where clinical results and drug approvals can quickly change the story. Still, it’s interesting to see a major investor looking beyond the usual AI and Big Tech names. Would you buy $RVMD based on the long-term biotech opportunity, or is the risk still too high?